Related Experiment Video

Updated: Feb 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications

Simona Camorani1, Elvira Crescenzi1, Monica Fedele1

  • 1Consiglio Nazionale delle Ricerche, Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore" (IEOS), Via S. Pansini 5, 80131 Naples, Italy.

Biochimica Et Biophysica Acta. Reviews on Cancer
|March 26, 2018
PubMed

Insights

Oligonucleotide aptamers offer a promising new strategy for targeting receptor tyrosine kinases (RTKs) in cancer therapy. These highly selective molecules overcome limitations of current treatments, paving the way for next-generation cancer drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Transmembrane receptor tyrosine kinases (RTKs) are critical in cancer development and progression.
  • Current therapies like antibodies and kinase inhibitors targeting RTKs have limitations, including efficacy and resistance.
  • There is a need for novel, highly selective anticancer agents.

Purpose of the Study:

  • To provide a comprehensive overview of oligonucleotide aptamers as a next-generation strategy for targeting RTKs in human cancers.
  • To highlight the advantages of aptamers over traditional therapies.

Main Methods:

  • Review of existing literature on oligonucleotide aptamers and RTK targeting.
  • Analysis of aptamer structure-function relationships for therapeutic applications.
  • Discussion of rational design strategies for aptamer development.

Main Results:

  • Oligonucleotide aptamers demonstrate high specificity and affinity for RTKs.
  • Aptamers can be rationally designed and modified for enhanced therapeutic potential.
  • Their nucleic acid nature simplifies development compared to antibodies.

Conclusions:

  • Oligonucleotide aptamers represent a powerful and versatile platform for next-generation cancer therapies targeting RTKs.
  • Aptamers offer a promising alternative to overcome current treatment challenges.
  • Further research into aptamer-based strategies can significantly advance cancer treatment.
Keywords:
AptamerCancer diagnosisCancer therapyRTKSELEXTargeted delivery

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.4K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
561
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.8K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.2K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K